Oral therapeutic - IntelGenx/Par Pharmaceutical
Latest Information Update: 16 Nov 2015
At a glance
- Originator IntelGenx Corp.; Par Pharmaceutical Inc
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Unspecified
Most Recent Events
- 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International
- 31 Mar 2012 Clinical trials in Undefined indication in Canada (PO)
- 21 Dec 2011 Investigation in Undefined indication in Canada (PO)